Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cynthia D Thompson

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Clinical Immunology (Orlando, Fla.)|April 23, 2003
Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cellsPetra Lenz, Cynthia D Thompson, Patricia M Day, et al.
FEBS Letters|March 21, 2002
NF-kappaB elements contribute to junB inducibility by lipopolysaccharide in the murine macrophage cell line RAW264.7Michelle R Frazier-Jessen, Cynthia D Thompson, Robert Brown, et al.
Plos Pathogens|July 15, 2006
Carrageenan is a potent inhibitor of papillomavirus infectionChristopher B Buck, Cynthia D Thompson, Jeffrey N Roberts, et al.
Molecular Therapy. Methods & Clinical Development|May 13, 2017
Efficient Production of Papillomavirus Gene Delivery Vectors in Defined In Vitro ReactionsCarla Cerqueira, Cynthia D Thompson, Patricia M Day, et al.
Journal of Virology|March 14, 2022
Chondroitin Sulfate Proteoglycans Are De Facto Cellular Receptors for Human Papillomavirus 16 under High Serum ConditionsNathan R Fons, Rhonda C Kines, Cynthia D Thompson, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 25, 2006
Human alpha-defensins block papillomavirus infectionChristopher B Buck, Patricia M Day, Cynthia D Thompson, et al.
Clinical and Vaccine Immunology : CVI|May 18, 2012
A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodiesPatricia M Day, Yuk-Ying S Pang, Rhonda C Kines, et al.
NPJ Vaccines|April 25, 2025
Repurposing anti-viral subunit and mRNA vaccines T cell immunity for intratumoral immunotherapy against solid tumorsShiv K Sethi, Claire E Bradley, Lukas Bialkowski, et al.
Journal of Virology|June 8, 2007
Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibitionPatricia M Day, Cynthia D Thompson, Christopher B Buck, et al.
Cancer Immunology Research|April 15, 2021
Virus-Like Particle-Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor AntigensRhonda C Kines, Cynthia D Thompson, Sean Spring, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Clinical Immunology (Orlando, Fla.)|April 23, 2003
Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cellsPetra Lenz, Cynthia D Thompson, Patricia M Day, et al.
FEBS Letters|March 21, 2002
NF-kappaB elements contribute to junB inducibility by lipopolysaccharide in the murine macrophage cell line RAW264.7Michelle R Frazier-Jessen, Cynthia D Thompson, Robert Brown, et al.
Plos Pathogens|July 15, 2006
Carrageenan is a potent inhibitor of papillomavirus infectionChristopher B Buck, Cynthia D Thompson, Jeffrey N Roberts, et al.
Molecular Therapy. Methods & Clinical Development|May 13, 2017
Efficient Production of Papillomavirus Gene Delivery Vectors in Defined In Vitro ReactionsCarla Cerqueira, Cynthia D Thompson, Patricia M Day, et al.
Journal of Virology|March 14, 2022
Chondroitin Sulfate Proteoglycans Are De Facto Cellular Receptors for Human Papillomavirus 16 under High Serum ConditionsNathan R Fons, Rhonda C Kines, Cynthia D Thompson, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 25, 2006
Human alpha-defensins block papillomavirus infectionChristopher B Buck, Patricia M Day, Cynthia D Thompson, et al.
Clinical and Vaccine Immunology : CVI|May 18, 2012
A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodiesPatricia M Day, Yuk-Ying S Pang, Rhonda C Kines, et al.
NPJ Vaccines|April 25, 2025
Repurposing anti-viral subunit and mRNA vaccines T cell immunity for intratumoral immunotherapy against solid tumorsShiv K Sethi, Claire E Bradley, Lukas Bialkowski, et al.
Journal of Virology|June 8, 2007
Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibitionPatricia M Day, Cynthia D Thompson, Christopher B Buck, et al.
Cancer Immunology Research|April 15, 2021
Virus-Like Particle-Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor AntigensRhonda C Kines, Cynthia D Thompson, Sean Spring, et al.
Pageof 4